NCT01673282View on ClinicalTrials.gov

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

CompletedOBSERVATIONAL
Enrollment

315

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Focal Epilepsy With and Without Secondary Generalization
Interventions
DRUG

Lacosamide

Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).

Trial Locations (42)

Unknown

60, Innsbruck

61, Mauer bei Amstetten

63, Ried

18, Berlin

34, Berlin

43, Berlin

66, Berlin

23, Bonn

28, Cologne

40, Cologne

25, Dortmund

35, Düsseldorf

48, Erbach im Odenwald

59, Erlangen

30, Essen

47, Giessen

29, Göttingen

37, Göttingen

05, Haag

12, Halle

19, Halle

39, Heidenheim

54, Ibbenbueren

27, Jena

04, Jülich

13, Kehl-Kork

36, Kiel

38, Leipzig

52, Magdeburg

67, Mainz

49, Mittweida

01, München

08, Oranienburg

17, Osnabrück

14, Radeberg

15, Rüsselsheim am Main

16, Senftenberg

41, Stuttgart

09, Troisdorf

22, Tübingen

20, Ulm

07, Westerstede

All Listed Sponsors
lead

UCB Pharma GmbH

INDUSTRY

NCT01673282 - Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy | Biotech Hunter | Biotech Hunter